FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054934928> ?p ?o ?g. }

• W2054934928 endingPage "54" @default.
• W2054934928 startingPage "49" @default.
• W2054934928 abstract "Background Talactoferrin alfa, a recombinant form of human lactoferrin, is a novel immunomodulatory protein with demonstrated ulcer healing properties in animal models. Methods A phase 1/2 clinical study was conducted at 7 clinical sites to determine if talactoferrin can improve wound healing in diabetic patients with foot ulceration. Fifty-five patients with diabetic neuropathic foot ulcers participated in this 2-phase study. In phase 1, groups of 3 patients each received open-label 1%, 2.5%, or 8.5% talactoferrin gel twice daily, in a sequential design, to their ulcer for 30 days. No drug-related adverse events were found at any dose level. Phase 2 was a randomized, placebo-controlled, single-blind study of 2.5% and 8.5% gels, with patients equally divided between the 3 groups. In combination with good wound care, treatment was administered topically twice daily to the ulcers for 12 weeks. The primary endpoint was the incidence of ≥75% healing (relative to baseline size). Results The study, which in phase 2 was powered to detect a difference between the placebo and combined talactoferrin arms with P < .1, met the primary objective. The groups receiving the 2.5% (n = 15) and 8.5% (n = 15) gels had twice the incidence of ≥75% reduction in ulcer size compared with the placebo group (n = 16): 47%, 53%, and 25%, respectively. On an intent-to-treat basis, the combination of the 2 active groups when compared with the placebo group showed a strong trend toward statistical significance (P = .09). There were no talactoferrin-related adverse events or laboratory abnormalities. Conclusions Topical talactoferrin appears to be safe and well tolerated and improves healing of diabetic neuropathic ulcers." @default.
• W2054934928 created "2016-06-24" @default.
• W2054934928 creator A5002786211 @default.
• W2054934928 creator A5007364645 @default.
• W2054934928 creator A5016269989 @default.
• W2054934928 creator A5017665613 @default.
• W2054934928 creator A5034035627 @default.
• W2054934928 creator A5045611437 @default.
• W2054934928 creator A5048728346 @default.
• W2054934928 creator A5053820847 @default.
• W2054934928 creator A5081687184 @default.
• W2054934928 creator A5086485786 @default.
• W2054934928 date "2007-01-01" @default.
• W2054934928 modified "2023-09-22" @default.
• W2054934928 title "Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study" @default.
• W2054934928 cites W1966012171 @default.
• W2054934928 cites W1988691104 @default.
• W2054934928 cites W2032666845 @default.
• W2054934928 cites W2037863500 @default.
• W2054934928 cites W2039433021 @default.
• W2054934928 cites W2051636690 @default.
• W2054934928 cites W2058365382 @default.
• W2054934928 cites W2069157301 @default.
• W2054934928 cites W2071589683 @default.
• W2054934928 cites W2078764619 @default.
• W2054934928 cites W2079238808 @default.
• W2054934928 cites W2088471638 @default.
• W2054934928 cites W2120472250 @default.
• W2054934928 cites W2124503827 @default.
• W2054934928 cites W2128094247 @default.
• W2054934928 cites W2137512342 @default.
• W2054934928 cites W2162520238 @default.
• W2054934928 doi "https://doi.org/10.1016/j.amjsurg.2006.07.010" @default.
• W2054934928 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17188087" @default.
• W2054934928 hasPublicationYear "2007" @default.
• W2054934928 type Work @default.
• W2054934928 sameAs 2054934928 @default.
• W2054934928 citedByCount "44" @default.
• W2054934928 countsByYear W20549349282012 @default.
• W2054934928 countsByYear W20549349282013 @default.
• W2054934928 countsByYear W20549349282014 @default.
• W2054934928 countsByYear W20549349282015 @default.
• W2054934928 countsByYear W20549349282016 @default.
• W2054934928 countsByYear W20549349282017 @default.
• W2054934928 countsByYear W20549349282018 @default.
• W2054934928 countsByYear W20549349282020 @default.
• W2054934928 countsByYear W20549349282021 @default.
• W2054934928 countsByYear W20549349282022 @default.
• W2054934928 crossrefType "journal-article" @default.
• W2054934928 hasAuthorship W2054934928A5002786211 @default.
• W2054934928 hasAuthorship W2054934928A5007364645 @default.
• W2054934928 hasAuthorship W2054934928A5016269989 @default.
• W2054934928 hasAuthorship W2054934928A5017665613 @default.
• W2054934928 hasAuthorship W2054934928A5034035627 @default.
• W2054934928 hasAuthorship W2054934928A5045611437 @default.
• W2054934928 hasAuthorship W2054934928A5048728346 @default.
• W2054934928 hasAuthorship W2054934928A5053820847 @default.
• W2054934928 hasAuthorship W2054934928A5081687184 @default.
• W2054934928 hasAuthorship W2054934928A5086485786 @default.
• W2054934928 hasConcept C120665830 @default.
• W2054934928 hasConcept C121332964 @default.
• W2054934928 hasConcept C126322002 @default.
• W2054934928 hasConcept C134018914 @default.
• W2054934928 hasConcept C141071460 @default.
• W2054934928 hasConcept C142724271 @default.
• W2054934928 hasConcept C168563851 @default.
• W2054934928 hasConcept C197934379 @default.
• W2054934928 hasConcept C203092338 @default.
• W2054934928 hasConcept C204787440 @default.
• W2054934928 hasConcept C27081682 @default.
• W2054934928 hasConcept C2777858829 @default.
• W2054934928 hasConcept C2778144972 @default.
• W2054934928 hasConcept C2779170986 @default.
• W2054934928 hasConcept C2780269544 @default.
• W2054934928 hasConcept C31760486 @default.
• W2054934928 hasConcept C535046627 @default.
• W2054934928 hasConcept C54355233 @default.
• W2054934928 hasConcept C555293320 @default.
• W2054934928 hasConcept C61511704 @default.
• W2054934928 hasConcept C63363279 @default.
• W2054934928 hasConcept C65409693 @default.
• W2054934928 hasConcept C71924100 @default.
• W2054934928 hasConcept C86803240 @default.
• W2054934928 hasConcept C90924648 @default.
• W2054934928 hasConceptScore W2054934928C120665830 @default.
• W2054934928 hasConceptScore W2054934928C121332964 @default.
• W2054934928 hasConceptScore W2054934928C126322002 @default.
• W2054934928 hasConceptScore W2054934928C134018914 @default.
• W2054934928 hasConceptScore W2054934928C141071460 @default.
• W2054934928 hasConceptScore W2054934928C142724271 @default.
• W2054934928 hasConceptScore W2054934928C168563851 @default.
• W2054934928 hasConceptScore W2054934928C197934379 @default.
• W2054934928 hasConceptScore W2054934928C203092338 @default.
• W2054934928 hasConceptScore W2054934928C204787440 @default.
• W2054934928 hasConceptScore W2054934928C27081682 @default.
• W2054934928 hasConceptScore W2054934928C2777858829 @default.
• W2054934928 hasConceptScore W2054934928C2778144972 @default.
• W2054934928 hasConceptScore W2054934928C2779170986 @default.

• next